TFS
LCTX icon

TrustCore Financial Services’s Lineage Cell Therapeutics LCTX Stock Holding History

TrustCore Financial Services’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$166 Hold
142
– – ﹤0.01% 1002
2022
Q3 		$0 Buy
+142
New +$209 ﹤0.01% 1123
2020
Q2 		– Sell
-4
Closed – – 919
2020
Q1 		$0 Hold
4
– – ﹤0.01% 929
2019
Q4 		$0 Hold
4
– – ﹤0.01% 938
2019
Q3 		$0 Hold
4
– – ﹤0.01% 970
2019
Q2 		$0 Hold
4
– – ﹤0.01% 923
2019
Q1 		$0 Buy
+4
New +$5 ﹤0.01% 843

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

TrustCore Financial Services's LCTX Position: Q4 2022 in Review

TrustCore Financial Services held its Lineage Cell Therapeutics (LCTX) position steady in Q4 2022 at 142 shares worth $166. The position accounts for ﹤0.01% of the portfolio, ranked #1002.

TrustCore Financial Services first reported a position in LCTX in Q1 2019 and has held it in 7 quarters since. 106 funds tracked by Wall St. Rank hold LCTX as of Q4 2022.

  • TrustCore Financial Services held 142 shares of Lineage Cell Therapeutics worth $166 as of Q4 2022.
  • TrustCore Financial Services left its Lineage Cell Therapeutics share count unchanged in Q4 2022.
  • Lineage Cell Therapeutics made up ﹤0.01% of TrustCore Financial Services's portfolio in Q4 2022, its #1002 holding.
  • TrustCore Financial Services first reported a position in Lineage Cell Therapeutics in Q1 2019 and has held it in 7 quarters since.
  • 106 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2022.

Based on TrustCore Financial Services's 13F filing for Q4 2022, filed 13 Feb 2023.